Treatment with recombinant porcine FVIII (rpFVIII) concentrate (susoctocog alfa) was first described in a prospective clinical trial that enrolled 28 patients with AHA and a history of a major bleeding event. This evidence concerns the gene F8 and autoimmune hemolytic anemia.